Sarepta Therapeutics Shares Drop Amid Multiple Analyst Downgrades, Patient Deaths

Sarepta Therapeutics has faced significant challenges in 2025 due to safety concerns surrounding its gene therapy treatment Elevidys, linked to acute liver failure and the deaths of two non-ambulatory Duchenne muscular dystrophy patients. These issues prompted the company to halt Elevidys shipments for non-ambulatory patients and suspend its fiscal year 2025 revenue guidance. As a result, multiple investment firms, including TD Cowen, Oppenheimer, William Blair, HC Wainwright & Co., and JPMorgan, have downgraded Sarepta's stock ratings and drastically reduced price targets, some by over 60%, reflecting uncertainty about the therapy's market viability and safety profile. Despite these setbacks, analysts remain divided, with the average price target around $54 and some maintaining an Outperform rating, while the stock has fallen over 88% in the past year to a 52-week low near $18. Sarepta's strong liquidity and significant revenue growth in Q1 2025 provide some stability as the company navigates regulatory scrutiny and market pressures. The biotechnology sector's volatility is underscored by Sarepta's situation, with investors closely monitoring future developments and safety data reviews.